International Medical Assistance

October 22, 2021

Cancer Medicine Pepaxto Withdrawn from Market

October 22, 2021 – Oncopeptides will withdraw Pepaxto® (melphalan flufenamide) from the United States market after a post-marketing clinical trial raised safety concerns
October 22, 2021

FDA Approves Expanded Indications for Cyltezo

October 22, 2021 – Cyltezo® (adalimumab-adbm – Boehringer Ingelheim) has received U.S. FDA approval to reduce the signs and symptoms of moderately to severely
October 20, 2021

Dupixent Asthma Indication Expanded

October 20, 2021 – Dupixent® (dupilumab) can now be used to treat asthma in a wider age group, as the U.S. FDA has expanded its asthma indication to include children ages